Literature DB >> 21335359

PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis.

P C M de Groot1, O M Dekkers, J A Romijn, S W M Dieben, F M Helmerhorst.   

Abstract

BACKGROUND: Patients with polycystic ovary syndrome (PCOS) are at risk of arterial disease. We examined the risk of (non)fatal coronary heart disease (CHD) or stroke in patients with PCOS and ovulatory women without PCOS, and assessed whether obesity might explain a higher risk of CHD or stroke.
METHODS: We performed a systematic review and meta-analysis of controlled observational studies. Four definitions of PCOS were considered: World Health Organization type II anovulation, National Institutes of Health criteria, Rotterdam consensus and Androgen-excess criteria. Obesity was defined as BMI > 30 kg/m(2) and/or waist circumference >88 cm. Study quality was assessed using the Newcastle-Ottawa Scale. Primary outcome was fatal/non-fatal CHD or stroke. Definitions of CHD and stroke were based on criteria used by the various authors. The effect measure was the pooled relative risk in a random effects model. Risk ratios and rate ratios were combined here.
RESULTS: After identifying 1340 articles, 5 follow-up studies published between 2000 and 2008 were included. The studies showed heterogeneity in design, definitions and quality. In a random effects model the relative risk for CHD or stroke were 2.02 comparing women with PCOS to women without PCOS (95% confidence interval 1.47, 2.76). Pooling the two studies with risk estimates adjusted for BMI showed a relative risk of 1.55 (1.27, 1.89).
CONCLUSIONS: This meta-analysis showed a 2-fold risk of arterial disease for patients with PCOS relative to women without PCOS. BMI adjustment did not affect this finding, suggesting the increased risk for cardiovascular events in PCOS is not completely related to a higher BMI in patients with PCOS.

Entities:  

Mesh:

Year:  2011        PMID: 21335359     DOI: 10.1093/humupd/dmr001

Source DB:  PubMed          Journal:  Hum Reprod Update        ISSN: 1355-4786            Impact factor:   15.610


  95 in total

1.  Inadequacy of initiating rosuvastatin then metformin on biochemical profile of polycystic ovarian syndrome patients.

Authors:  G Ghazeeri; H A Abbas; B Skaff; S Harajly; J Awwad
Journal:  J Endocrinol Invest       Date:  2015-02-27       Impact factor: 4.256

2.  Impact of hormonal contraception and weight loss on high-density lipoprotein cholesterol efflux and lipoprotein particles in women with polycystic ovary syndrome.

Authors:  Anuja Dokras; Martin Playford; Penny M Kris-Etherton; Allen R Kunselman; Christy M Stetter; Nancy I Williams; Carol L Gnatuk; Stephanie J Estes; David B Sarwer; Kelly C Allison; Christos Coutifaris; Nehal Mehta; Richard S Legro
Journal:  Clin Endocrinol (Oxf)       Date:  2017-03-09       Impact factor: 3.478

3.  Polycystic ovary syndrome (PCOS): metformin.

Authors:  David J Cahill; Katherine O'Brien
Journal:  BMJ Clin Evid       Date:  2015-03-27

Review 4.  Adverse Pregnancy Conditions, Infertility, and Future Cardiovascular Risk: Implications for Mother and Child.

Authors:  Ki Park; Janet Wei; Margo Minissian; C Noel Bairey Merz; Carl J Pepine
Journal:  Cardiovasc Drugs Ther       Date:  2015-08       Impact factor: 3.727

Review 5.  Targets to treat metabolic syndrome in polycystic ovary syndrome.

Authors:  Shruthi Mahalingaiah; Evanthia Diamanti-Kandarakis
Journal:  Expert Opin Ther Targets       Date:  2015-10-21       Impact factor: 6.902

6.  Assessing the intersection of cardiovascular disease, venous thromboembolism, and polycystic ovary syndrome.

Authors:  Ekwutosi M Okoroh; Sheree L Boulet; Mary G George; W Craig Hooper
Journal:  Thromb Res       Date:  2015-10-17       Impact factor: 3.944

Review 7.  Cardiovascular and metabolic risks associated with PCOS.

Authors:  Rhoda H Cobin
Journal:  Intern Emerg Med       Date:  2013-04       Impact factor: 3.397

8.  The importance of speckle tracking echocardiography in the early detection of left ventricular dysfunction in patients with polycystic ovary syndrome.

Authors:  Selami Demirelli; Husnu Degirmenci; Emrah Ermis; Sinan Inci; Gokay Nar; Mehmet Emin Ayhan; Serdar Fırtına; Hikmet Hamur; Senay Arikan Durmaz
Journal:  Bosn J Basic Med Sci       Date:  2015-10-19       Impact factor: 3.363

9.  Calcitriol attenuates cardiac remodeling and dysfunction in a murine model of polycystic ovary syndrome.

Authors:  Ling Gao; Jia-Tian Cao; Yan Liang; Yi-Chao Zhao; Xian-Hua Lin; Xiao-Cui Li; Ya-Jing Tan; Jing-Yi Li; Cheng-Liang Zhou; Hai-Yan Xu; Jian-Zhong Sheng; He-Feng Huang
Journal:  Endocrine       Date:  2015-11-17       Impact factor: 3.633

10.  Lack of Association of Vitamin D Receptor FokI (rs10735810) (C/T) and BsmI (rs1544410) (A/G) Genetic Variations with Polycystic Ovary Syndrome Risk: a Case-control Study from Iranian Azeri Turkish Women.

Authors:  Morteza Bagheri; Isa Abdi Rad; Nima Hosseini Jazani; Fariba Nanbakhsh
Journal:  Maedica (Buchar)       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.